‘Three-Year Myopia Control Efficacy of DOT Spectacle Lenses in Young Children’ (Laughton D., et al.) centres on a sub-group six- to seven-year-olds who participated in the company’s pivotal CYPRESS clinical trial. Investigators had expectations of highly progressive myopia and a paucity of efficacy data for this age group.
After three years, SightGlass Vision reported that myopia progression among these young children was limited to <1.00 D in 60% of Diffusion Optics Technology (DOT) 0.2 spectacle lens wearers. This was compared to 21% of control lens wearers. This data – shared for the first time at BCLA – reinforces previously announced safety and efficacy outcomes.
Spectacle lenses with the company’s DOT use thousands of micro-dots to softly scatter light to reduce contrast on the retina, described as a unique mechanism of action to control myopia progression in children. During the past 18 months, this patent-protected technology has been launched in several markets, including China, the Netherlands, and Israel, as well as preliminary market trials in other countries.
Also debuting at BCLA was: ‘Peripheral Visual Function with DOT Spectacle Lenses for Myopia Control’ (Aboualizadeh E., et al.). This study taps into the “rich CYPRESS data set” to review long-term changes in peripheral visual acuity (VA) after three years of DOT spectacle lens wear.
Compared to the baseline, peripheral VA improved or remained stable, with no significant differences between the DOT and standard single-vision groups, SightGlass reported.
“We are deeply committed to advancing myopia control, evidenced by our presentations at the BCLA Conference plus recent efficacy, safety, and visual performance data reporting at ARVO in North America and COOC in China,” Mr Andrew Sedgwick, CEO of SightGlass Vision, said.
“Eyecare professionals can confidently prescribe Diffusion Optics Technology spectacle lenses, knowing the outcomes are supported by extensive science.”